Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
7 participants
INTERVENTIONAL
2014-05-31
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The length of the study is 6 months. Treatment will last 24 weeks, the participants will attend group sessions (60-90 mins.) on a weekly basis for weeks 1-12 and then every other week for weeks 14-24, for a total of 18 treatments. Treatment will include meal replacement, education on nutrition and proper eating habits as well as behavior modification and skills which is known to be effective.
Participants will be scheduled to come to the Bariatric Center for the first assessment/screening and for the consenting process. TGH+USF Bariatric Center has dedicated clinical space in their suite with private exam rooms, an education classroom, and private testing room.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ketogenic diet
Weight management on a male population of retired NFL athletes.
Ketogenic diet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ketogenic diet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Former NFL players
* Aged 25-64 (Age range is chosen to keep participants as uniform as possible given the small number of participants. The majority of the players are in this age range and participants need to be able to exercise and be active. Also the NFL in its current form was created in 1970 so there are very few players that are retired from the NFL that are over the age of 65.)
* BMI \>27
* English- speaking
Exclusion Criteria
* Significant Cardiovascular Disease (recent \< 1 year Myocardial Infarction, hospital admission \< 1year for Congestive Heart Failure, Active Angina, exercise induced Angina)
* Malignant arrhythmias (VTACH, AFIB, Aflutter)
* Renal Disease ( Dialysis or Chronic Renal Insufficiency)
* Hepatic Disease ( Hepatitis B and C or Liver function test 2.5 times the upper limits of normal, or liver transplant that requires immune odulating/suppressing medications, ammonia lowering medications, or hepatic disease related to diet modification).
* Psychosis, Severe Anxiety, or Major Depression
* Significant migraines requiring abortive medication in the last year
* Significant Endocrine dysfunction ( Cushing's Syndrome )
* Uncontrolled Hypertension \> 160/90
* Severe arthritis that significantly limits mobility
* Uncontrolled Hyper/Hypothyroidism
* Obesity Surgery in the past
* Weight loss of greater than 10% of the subjects body weight in the last year
* Recent history (within 1 year ) of Alcohol abuse, illegal Drug abuse
* Active pulmonary disease that requires daily corticosteroids, an oxygen requirement, or ventilation support for chronic disease management.
* Participants currently taking or having been taking within the last 3 months the following medication will be excluded.
* Appetite Suppressants (Phenterimine, Qsymia)
* Anti-obesity medications (Xenical/Meridia)
* Corticosteroids or \> 1500 micrograms of inhaled steroids daily
* Raloxifene (Evista) or Temoxifene (HRT medications)
* Inappropriate use of Testosterone
* At the discretion of the investigator use of Psychiatric Medication, Sedative/Hypnotics, Benzodiazepines
* Detailed Disease and Lab Value Exclusion
* Active rheumatologic, dermatologic disease, or autoimmune/inflammatory condition will be defined as any patient who currently, or has a past medical history of chronic (\>2 weeks) immune modulating/suppressing medications.
* Active renal disease will be defined as any patient who is currently, or has a history requiring potassium phosphate lowering medication, protein restriction diet, or hemo/peritoneal dialysis
* Screening creatinine \>1.5
* Serious or unstable medical or psychological condition that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study
* Participants with screening triglycerides above 500 mg.
* Uncontrolled Dyslipidemia as defined by screening LDL cholesterol \>160 mg/dL. Participants on medication treating dyslipidemia for at least 3 months are allowable.
* Neuropathy that interferes with exercise.
* Previous weight loss surgery
* Lab value exclusions are limited to all routine electrolyte values outside the normal range, except glucose.
25 Years
64 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tampa General Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Gonzalvo, DO
Role: PRINCIPAL_INVESTIGATOR
Tampa General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tampa General Hospital
Tampa, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TGH0002
Identifier Type: -
Identifier Source: org_study_id